The genetics decide the treatment line. The clinician should not have to wait two weeks to see them.
That is how long a sequencing panel takes to call NPM1, FLT3, and the rest. For two weeks the lesions that move a patient across a treatment line are a blank the clinician waits on.
Axiisium reads the molecular signal from the Day-1 bone-marrow morphology and signs a provisional prediction the same day, then resolves it against the confirmatory assay on a single cryptographic chain of custody. Not AI that guesses. AI that attests.
The image model reads the smear and issues a probability, signed on the spot and marked pending wet-lab confirmation. The clinician can start planning; the record never calls it confirmed.
The wet-lab result resolves the Day-1 prediction on the same chain. Agree or disagree, the record shows exactly what was predicted and what was confirmed. Nothing is quietly rewritten.
Models commoditize. A verifiable, signed chain from Day-1 prediction to confirmed genotype does not. That chain is the product.
Research use only. AI-predicted from morphology; provisional, pending wet-lab NGS confirmation. Not a diagnosis.